Cargando…

Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases

INTRODUCTION: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease. Epidermal growth factor receptor (EGFR) inhibitors may have a role in this se...

Descripción completa

Detalles Bibliográficos
Autores principales: Callegaro-Filho, Donato, Kavanagh, John J., Nick, Alpa M., Ramirez, Pedro T., Schmeler, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934679/
https://www.ncbi.nlm.nih.gov/pubmed/24575024
http://dx.doi.org/10.1159/000358916
_version_ 1782305086431559680
author Callegaro-Filho, Donato
Kavanagh, John J.
Nick, Alpa M.
Ramirez, Pedro T.
Schmeler, Kathleen M.
author_facet Callegaro-Filho, Donato
Kavanagh, John J.
Nick, Alpa M.
Ramirez, Pedro T.
Schmeler, Kathleen M.
author_sort Callegaro-Filho, Donato
collection PubMed
description INTRODUCTION: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease. Epidermal growth factor receptor (EGFR) inhibitors may have a role in this setting. CASE DESCRIPTION: A 53-year-old woman with stage IB2 squamous cell carcinoma of the cervix was initially treated with chemoradiation. Six months after completing treatment, she developed a recurrence in the common iliac and para-aortic lymph nodes above the previous radiation field and was treated with additional radiation therapy. Two years later, she developed recurrent disease in the left supraclavicular lymph nodes and was treated with chemoradiation followed by 3 cycles of adjuvant cisplatin and topotecan. She had a complete response and was placed on maintenance therapy with topotecan and erlotinib, which was well tolerated and produced minimal side effects. After 20 months of maintenance therapy, it was discontinued given the long interval without evidence of disease. The patient is currently without evidence of disease 5 years after completing the topotecan-erlotinib treatment. CONCLUSION: We noted a sustained response in a patient with recurrent metastatic cervical cancer treated with radiotherapy, cisplatin, and topotecan followed by maintenance therapy with topotecan and erlotinib. Further evaluation of the role of EGFR inhibitors in this setting should be considered given their favorable toxicity profile and biological relevance.
format Online
Article
Text
id pubmed-3934679
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-39346792014-02-26 Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases Callegaro-Filho, Donato Kavanagh, John J. Nick, Alpa M. Ramirez, Pedro T. Schmeler, Kathleen M. Case Rep Oncol Published online: January, 2014 INTRODUCTION: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease. Epidermal growth factor receptor (EGFR) inhibitors may have a role in this setting. CASE DESCRIPTION: A 53-year-old woman with stage IB2 squamous cell carcinoma of the cervix was initially treated with chemoradiation. Six months after completing treatment, she developed a recurrence in the common iliac and para-aortic lymph nodes above the previous radiation field and was treated with additional radiation therapy. Two years later, she developed recurrent disease in the left supraclavicular lymph nodes and was treated with chemoradiation followed by 3 cycles of adjuvant cisplatin and topotecan. She had a complete response and was placed on maintenance therapy with topotecan and erlotinib, which was well tolerated and produced minimal side effects. After 20 months of maintenance therapy, it was discontinued given the long interval without evidence of disease. The patient is currently without evidence of disease 5 years after completing the topotecan-erlotinib treatment. CONCLUSION: We noted a sustained response in a patient with recurrent metastatic cervical cancer treated with radiotherapy, cisplatin, and topotecan followed by maintenance therapy with topotecan and erlotinib. Further evaluation of the role of EGFR inhibitors in this setting should be considered given their favorable toxicity profile and biological relevance. S. Karger AG 2014-01-31 /pmc/articles/PMC3934679/ /pubmed/24575024 http://dx.doi.org/10.1159/000358916 Text en Copyright © 2014 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: January, 2014
Callegaro-Filho, Donato
Kavanagh, John J.
Nick, Alpa M.
Ramirez, Pedro T.
Schmeler, Kathleen M.
Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases
title Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases
title_full Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases
title_fullStr Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases
title_full_unstemmed Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases
title_short Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases
title_sort sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases
topic Published online: January, 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934679/
https://www.ncbi.nlm.nih.gov/pubmed/24575024
http://dx.doi.org/10.1159/000358916
work_keys_str_mv AT callegarofilhodonato sustainedcompleteresponseaftermaintenancetherapywithtopotecananderlotinibforrecurrentcervicalcancerwithdistantmetastases
AT kavanaghjohnj sustainedcompleteresponseaftermaintenancetherapywithtopotecananderlotinibforrecurrentcervicalcancerwithdistantmetastases
AT nickalpam sustainedcompleteresponseaftermaintenancetherapywithtopotecananderlotinibforrecurrentcervicalcancerwithdistantmetastases
AT ramirezpedrot sustainedcompleteresponseaftermaintenancetherapywithtopotecananderlotinibforrecurrentcervicalcancerwithdistantmetastases
AT schmelerkathleenm sustainedcompleteresponseaftermaintenancetherapywithtopotecananderlotinibforrecurrentcervicalcancerwithdistantmetastases